<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325560</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-6791</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Alternative therapies in health and medicine</Title><ISOAbbreviation>Altern Ther Health Med</ISOAbbreviation></Journal><ArticleTitle>Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.</ArticleTitle><Pagination><StartPage>12</StartPage><EndPage>17</EndPage><MedlinePgn>12-17</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">AT11423</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Moderate to severe interstitial cystitis (also known as bladder pain syndrome) is a disabling disease with no effective treatment. Although pentosan polysulfate is an approved treatment for interstitial cystitis, some patients on this medication experience treatment failure after one year, and its long-term use has been linked to pigmentary maculopathy. The peptide Body Protective Compound 157 (BPC-157) is a possible treatment for interstitial cystitis but is currently not approved by the US Food and Drug Administration.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the safety and efficacy of BPC-157 manufactured by a 503A compounding pharmacy as a treatment for interstitial cystitis.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">Twelve women between the ages of 39 and 76 years with a mean age of 58.3 years participated in this trial at a private clinic. Of these, 10 were White, one was Asian, and one was Latina. None of the 12 women had responded to pentosan polysulfate.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The women underwent cystoscopy and were treated with injections of the peptide BPC-157 (total of 10 mg) around the area of inflammation of the bladder during a single procedure. Global Response Assessment questionnaire was given to all the subjects to assess the efficacy of BPC-157.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Complete resolution of symptoms after one treatment was reported in 10 of 12 patients, who rated their success at 100%. The remaining 2 of 12 patients rated their success at 80%, with most symptoms resolved but about 20% of their symptoms lingering. No one dropped out of the study, and no adverse events were reported. This therapy was successful because all 12 patients scored a 5/5 on the Global Response Assessment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This is the first report of intravesical BPC-157 (10 mg) injection to help patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edwin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ayadi</LastName><ForeName>Bahram</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Altern Ther Health Med</MedlineTA><NlmUniqueID>9502013</NlmUniqueID><ISSNLinking>1078-6791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>37300-21-3</RegistryNumber><NameOfSubstance UI="D010426">Pentosan Sulfuric Polyester</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018856" MajorTopicYN="Y">Cystitis, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010426" MajorTopicYN="N">Pentosan Sulfuric Polyester</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325560</ArticleId><ArticleId IdType="pii">AT11423</ArticleId></ArticleIdList></PubmedData></PubmedArticle>